ERBB2 and breast carcinoma: Figure 6H illustrated the different viabilities of breast cancer organoids treated with the HER2 inhibitor lapatinib (0.4 μM), the PI3K inhibitor BYL719 (1 μM) or the combination of two drugs at Day 1, Day 3 and Day 5.